ENTRY       D10400                      Drug
NAME        Tildrakizumab (USAN);
            Tildrakizumab (genetical recombination) (JAN);
            Tildrakizumab-asmn;
            Ilumya (TN)
PRODUCT     ILUMYA (Sun Pharmaceutical Industries)
FORMULA     C6426H9918N1698O2000S46
EXACT_MASS  144345.3728
MOL_WEIGHT  144434.6737
SEQUENCE
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC17
            Product: D10400<JP/US>
EFFICACY    Antipsoriatic, Immunosuppressant, Anti-IL-23 antibody
  DISEASE   Plaque psoriasis [DS:H01656]
  TYPE      Monoclonal antibody
COMMENT     Treatment of immunologically mediated inflammatory disorders
TARGET      IL23A [HSA:51561] [KO:K05426]
  PATHWAY   hsa04060(51561)  Cytokine-cytokine receptor interaction
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC17 Tildrakizumab
                  D10400  Tildrakizumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Tildrakizumab
                 D10400  Tildrakizumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D10400  Tildrakizumab (USAN); Tildrakizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10400  Tildrakizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10400  Tildrakizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL23A
                 D10400  Tildrakizumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10400
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10400
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10400
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10400
DBLINKS     CAS: 1326244-10-3
            PubChem: 172232493
///
